November 28, 2024

CRC 1249 – Funding for Collaborative Research Centre in Chemistry

CRC 1249 – Funding for Collaborative Research Centre in Chemistry

The German Research Foundation providing funding of around 10,9 million euros

With a Collaborative Research Centre in chemistry, Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG). The CRC 1249 “N-Heteropolycycles as Functional Materials”, where research is being carried out on novel organic compounds, is entering its third funding period. The DFG is providing funding of around 10,9 million euros for the research consortium over a period of four years. Prof. Dr Petra Tegeder from the Institute for Physical Chemistry at Ruperto Carola will serve as spokesperson.

Petra Tegeder
Petra Tegeder | © private

The focus of CRC 1249 is the development of novel organic functional materials with specifically tunable electronic and optical properties and their application as photoactive components and organic semiconductors. This is done on the basis of a large and flexibly variable class of organic hydrocarbon compounds with ring structures containing nitrogen atoms. The research plan comprises the development of synthetic-chemical methods, structural and spectroscopic characterization as well as the theoretical modeling of molecules, aggregates and solid films. Of particular interest is the way in which molecular properties are related to the optoelectronic properties of materials and devices.

The Collaborative Research Centre is supported by researchers from the three Institutes of Chemistry, the Interdisciplinary Center for Scientific Computing and the Institute for Molecular Systems Engineering and Advanced Materials at Heidelberg University. Research groups from the Karlsruhe Institute of Technology and the Max Planck Institute for Solid State Research in Stuttgart are also participating. The CRC 1249 will reach the maximum funding period of twelve years.

Further information

Participating Institutions

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp